

A First Order Phase Transition Underlies the Formation of Sub-Diffractive Protein Aggregates in Mammalian Cells

Arjun Narayanan¹, Anatoli B. Meriin², Michael Y. Sherman², Ibrahim I. Cissé¹

1. Department of Physics, MIT, Cambridge, MA

2. Department of Biochemistry, Boston University School of Medicine, Boston, MA

Correspondence: Ibrahim Cissé, icisse@mit.edu

ABSTRACT: Failure in protein quality control can often lead to protein aggregation, yet in neurodegenerative diseases, by the time aggregates can be seen, the cells have advanced well into the disease pathology. Here, we develop a quantitative imaging approach to study the protein aggregation process in living mammalian cells with unprecedented spatio-temporal resolution. We find that sub-diffractive precursor aggregates may form even in untreated cells, and their size distribution is exactly as predicted for a system undergoing a first order phase transition. Practically, this implies that as soon as aggregates reach a critical size ($R_c = 162 \pm 4$ nm untreated cells), they will spontaneously grow into large inclusions. Our data suggest that a previously uncharacterized, RuvBL1 dependent mechanism clears aggregates above the critical size. Our study unveils the existence of sub-diffractive aggregates in living cells; and the strong agreement between cellular data and a nucleation theory, based on first order phase transition, provides insight into regulatory steps in the early stages of aggregate formation in vivo.

23 Neurodegenerative diseases, such as Parkinson's Disease, Amyotrophic Lateral Sclerosis, and
24 Alzheimer's Disease, are characterized by the appearance of large protein aggregates in cells and in
25 the extracellular space (1). It is hypothesized that intermediate species in the aggregation process are
26 likely more toxic moieties (2-9) than conventionally visible large aggregates, plaques or fibres.
27 However detecting and characterizing intermediate aggregates remains a fantastic technical challenge.
28 Capturing the early steps of protein aggregation in living cells can help uncover hidden mechanisms
29 in their formation and regulation in vivo, as well as elucidate their putative roles in protein misfolding
30 diseases (2-9).

31 Here we develop a quantitative super-resolution assay to study the early steps protein
32 aggregation in mammalian cells. We adopt proteasome inhibition as an approach used to study the
33 formation of large aggregates in living mammalian cells (10-13). Treatment of cells with the
34 proteasome inhibitor MG132 (14) leads to the gradual accumulation of misfolded, aggregation-prone
35 proteins, and to the formation of the aggresome, a large juxta-nuclear inclusion body akin to Lewy
36 bodies (15, 16) in Parkinson's disease cells. We engineered mammalian cell lines expressing
37 Synphilin 1 - a marker of aggregates in Parkinson's disease (10, 17, 18) - fused to a fluorescent
38 protein Dendra2 (19). Dendra2 is a green to red photo-convertible protein that enables photo-
39 activation localization microscopy (PALM) (20), a single-molecule based super-resolution (20-22)
40 approach we used previously to quantitatively image protein clustering with high spatio-temporal
41 resolutions in living cells (23, 24).

42 Imaging Synphilin 1 by conventional fluorescence, shows emergence of the aggresome
43 around 135 minutes after treatment (**Fig. 1A-E**, top panels and **supplementary movie 1**) but
44 formation dynamics of the aggresome cannot be readily measured with this imaging approach.
45 Instead, when we perform live cell super-resolution imaging (25) (**Fig. 1A-E**, bottom panels), we can
46 detect and quantify the growth of individual aggresomes (**Fig. 1F**), from their inception at length
47 scales unattainable in previous live cell studies (26). Furthermore, in addition to the large aggresome,
48 the examination of **Fig. 1A-E** (bottom panels and **supplementary movie 1**) shows a population of
49 sub-diffractive aggregates throughout the cellular cytoplasm and indiscernible in the conventional

50 images (top panels). Thus, our live cell super-resolution imaging approach reveals a previously
51 undetected population of sub-diffractive aggregates.

52 We characterize the properties of these sub-diffractive aggregates using density based spatial
53 clustering of applications with noise (DBSCAN) (27). We record for each aggregate, the radius, and
54 the number of localization events (fluorescence detection events) ((25) and **supplementary text 1**).
55 Only aggregates with a radius greater than our localization accuracy (estimated to be ~20nm (23)) are
56 interpreted in our analysis; aggregates of radius less than 25nm are discarded.

57 As represented in **Fig. 1G**, we find that the number of localization events per aggregate is
58 proportional to the radius cubed (volume) of the aggregate (also see **supplementary text 1**). This
59 observation implies that sub-diffractive aggregates have a defined density, with the aggregate size
60 scaling linearly with volume. Relying on the precise number of molecular detections to estimate
61 aggregate size can be complicated by single molecule photo-physical variability (28). Here, we rely
62 on the existence of a well-defined density to use the spatial extent (radius cubed) of the aggregate as
63 the measure of the size. For subsequent theoretical analyses, we found it practical to define the
64 aggregate size as a reduced numerical parameter ‘*n*’ (see **supplementary text 1**, and **Fig. S1**).

65 Previous studies, from experiments done in vitro, have invoked nucleation and growth as a
66 potential mechanism underlying aggregate formation (29). However, such models imply that
67 aggregation occurs through a first order phase transition into a so-called state of *super-saturation*,
68 characterized by a well-defined nucleation barrier (30). The nucleation barrier reflects a critical
69 aggregate size above which spontaneous growth is energetically favoured, and below which aggregate
70 disassembly is favoured. Such a critical aggregate size, if it exists, has been difficult to measure
71 experimentally (29), due in part to the challenge of detecting the stochastically formed, transient
72 precursor clusters; and it is unclear even if proven in vitro, whether phase transition formalism may
73 still hold inside the cells where complex biological quality control mechanisms exist. If a first order
74 phase transition is pertinent, there are clear theoretical expectations for the distribution and evolution
75 of aggregate sizes. Therefore, we investigate the mechanism behind sub-diffractive aggregates

76 formation and growth in mammalian cells, initially, by studying the size distribution of the
77 aggregates, and how the distribution evolves with time.

78 In nucleation and growth a system may be either in a *sub-saturated* state (**Fig. 2A**), or in a
79 *super-saturated* state (**Fig. 2B & C**). In the first case the formation and growth of sub-diffractive
80 aggregates is not favoured energetically. In such a *sub-saturated* system, an exponential distribution
81 of aggregate sizes is expected (30, 31). For a *sub-saturated* state, the overall distribution of aggregate
82 sizes does not change with time even as individual aggregates may grow or disassemble
83 (**supplementary text 2**, and simulations in **Fig. 2D**).

84 Alternatively, in a *super-saturated* state, the system is poised such that aggregates that
85 stochastically reach the critical size become energetically favoured to grow spontaneously (see
86 **supplementary text 2** and **Fig. S2**). In such a case the distribution of aggregate sizes is time-
87 evolving (simulations in **Fig. 2E& F**) and may result in a peak at large aggregate sizes when the total
88 pool of contributing proteins is conserved (**Fig. 2E**). Alternatively, the pool of contributing proteins
89 may be continuously replenished, leading to an exponential distribution of small aggregates coexisting
90 with a growing shoulder at larger aggregate sizes (**Fig. 2F**); This may likely be the case in living cells
91 when new misfolded proteins can constantly be added to the system. As represent in **Fig. 2G** our
92 super-resolution data reveals a distribution of aggregate sizes with a shoulder growing towards larger
93 aggregates, as a function of time after treatment, more consistent with the simulations in **Fig. 2F**. This
94 result suggests that sub-diffractive aggregate formation and time evolution may behave as a *super-*
95 *saturated* condensation system.

96 A *super-saturated* system is expected to exhibit precise energetics, underlain by a critical
97 aggregate size (30) (noted here as n_c or R_c). n_c (or R_c) is the point at which the surface energy cost
98 is balanced by the minimising energy of the molecules buried in the bulk of the aggregate. In
99 particular the expected form of the free energy cost to form a aggregate of size “n”, is given
100 by $U(n) = an^{2/3} - bn$, with two terms ($an^{2/3}$ and bn) representing the surface and bulk
101 contributions respectively (**supplementary text 2**, and **Fig. S2**). Moreover, in this formalism, for

102 aggregates below the critical size (i.e $n < n_c$) the Boltzmann distribution ($P(n) \propto e^{-U(n)}$), the
103 equilibrium thermodynamics exponentially-suppressed distribution, would be expected even though
104 the full system may not be in equilibrium (30).

105 We examine whether the sub-diffractive aggregates in the mammalian cells truly exhibit such
106 stringent energetics. Given that for a *super-saturated* system the sub-critical aggregate ($n < n_c$) size
107 distribution may be approximated as $P(n) \propto e^{-U(n)}$ ($n < n_c$), then the negative logarithm should
108 give the free energy cost $U(n)$, i.e $-\text{Log}(P(n)) \propto U(n)$, for $n < n_c$. By plotting the negative
109 logarithm of the size distribution one can test how well the distribution is governed by the precise
110 free energy cost $U(n) = an^{2/3} - bn$ (see prediction in **Fig. 3A**). We find a remarkable agreement
111 between the experimentally measured sub-critical size distribution shown in **Fig. 3B** and this very
112 specific prediction of simple condensation theory (see (25) and **supplementary text 2**).

113 The agreement between theory and experiment in **Fig. 3B** involves a fit with two model-
114 parameters (surface and bulk terms respectively). We test even further whether the two terms can be
115 decoupled. That is, whether a fit of the only the surface term at a physically appropriate limit, would
116 result in a data-set which is accounted for primarily by the remaining bulk term.

117 The surface term ($an^{2/3}$) must dominate for very low- n . Thus we posit that by fitting only
118 the first few data points of the $-\text{Log}(P(n))$ graph to the surface term $an^{2/3}$, and subtracting it off
119 of the data (25), then for all remaining sub-critical aggregates the resultant should be the volume term,
120 i.e. $[-\text{Log}(P(n)) - an^{2/3}] \propto -bn$. This resultant should be a straight line when plotted versus
121 aggregate size n , (see theoretical prediction in **Fig. 3C**). We note that there is, a-priori, nothing else
122 in our dataset imposing that the resulting data should be linear upon correction of the surface term.
123 Thus if the data deviate from the first order phase transition energetics, we would expect a scattered
124 resultant, or the revelation of a different energy dependence. In **Fig. 3D** the data show a strikingly
125 linear resultant, demonstrating a high quality agreement between the theory and super-resolution
126 experimental data.

127 From the results in **Fig. 3**, therefore, we conclude that while other bio-regulatory processes
128 might be at play, the simple condensation picture with specific energetic dependence $U(n) = an^{2/3} -$
129 bn , describes how sub-diffractive aggregates can form and grow to a well-defined critical size n_c in
130 the mammalian cells. We also tested aggregates with the Neuro2A cell line (neuronal precursor cells,
131 see **supplementary text 3**) and observe the very same conclusions (**Fig. S3**) suggesting the physical
132 mechanism for sub-diffractive aggregation may be general to a range of mammalian cells.

133 Biochemically, the specific parameters in the energetics for nucleation and growth would
134 depend on the concentration of aggregating proteins and on their effective energy of interactions. To
135 further test this notion, we sought to increase the concentration of misfolded aggregating polypeptides
136 in living cells by incubation with a proline analog azetidine-2-carboxylic acid (AZC). This molecule
137 incorporates in newly synthesized polypeptides instead of proline, and prevents normal folding, thus
138 generating a massive build-up of misfolded proteins in the cell (32). In a condensation model, such a
139 build-up would result in a greater degree of *super-saturation* with a stronger bulk (linear) term.

140 We find in **Fig. 3E&F** that the distribution of aggregates sizes in the presence of AZC fits the
141 same functional form, and with a larger linear slope indicative of a larger bulk term (also see further
142 AZC characterization in **supplementary text 4, Fig. S4** and general applicability of our results under
143 other perturbations in **supplementary text 5, Fig. S5**). The AZC incubation data further validates the
144 agreement between cellular aggregation data and the nucleation model, and with interpretations
145 consistent with that expected of a classical *super-saturated* system.

146 Implicit to phase transition theory is the notion that any cell including healthy cells or those
147 untreated with proteasome inhibitor, may readily form sub-diffractive aggregates which
148 spontaneously grow into large inclusions after reaching n_c . This expectation is counter to a widely
149 held belief that the presence of precursor aggregates may directly indicate cell pathology (2). In **Fig.**
150 **4A** (left panel) we find that untreated cells do in fact show sub-diffractive aggregates implying that
151 aggregates readily formed inside the cell without chemical treatments.

152 However, untreated cells are distinctly void of large super-critical aggregates. A violin plot
153 of aggregate sizes from untreated cells (**Fig. 4C**, black) indicates that while a large population of
154 small aggregate sizes is apparent (indicated by the width of the violin plot in **Fig. 4C**), untreated cells
155 do not have a significant population of large aggregates. For instance we rarely found aggregates of
156 radius greater than 250nm in untreated cells. We measure the critical radius to be $R_c = 162 \pm 4$ nm for
157 untreated cell (**Fig. 4D**, black bar, see Supplementary text 2 for calculation of n_c or R_c). Therefore,
158 despite the fact that clusters should reach n_c and then stably grow, such a population of super-critical
159 clusters seems to be suppressed in healthy cells. These results imply that a hidden mechanism may
160 exist to clear the cells of super-critical aggregates (i.e. aggregates that have reached sizes greater than
161 the critical radius) in untreated cells.

162 We sought to test whether a clearance pathway could account for the absence of super-critical
163 aggregates in untreated cells. Because a AAA+ ATPase, RuvBL, was previously suggested as a
164 potential protein disaggregase in mammalian cells and in yeast (33), we tested whether RuvBL may
165 be involved in the preferential clearance of super-critical aggregates. We find that knocking down
166 RuvBL1 in untreated cells, results in the appearance of large aggregates (**Fig. 4B**, compare to
167 untreated cell **Fig. 4A**). A violin plot of aggregate sizes from RuvBL1 knocked-down cells shows a
168 clear population of large aggregate sizes, with some aggregates with radii greater than $1 \mu m$, a size
169 range that could only be observed previously after hours of proteasome inhibition (**Fig. 4C**). These
170 results implicate RuvBL1 in the clearance of large aggregates from untreated cells (see
171 **supplementary text 6**, and **Fig. S6** for further tests of RuvBL1).

172 Importantly, we find that upon RuvBL1 knockdown, $R_c = 157 \pm 6$ nm did not change
173 significantly from R_c in control untreated cells (162 ± 4 nm) (**Fig. 4D**) suggesting that RuvBL1
174 knockdown did not significantly change the sub-critical distribution. This observation implies that
175 RuvBL1 did not affect the concentration of aggregating molecules or their interactions, unlike, for
176 instance, proteasome inhibition which gradually reduced R_c (**Fig. 4D**). Indeed, depletion of RuvBL1
177 prevented clearance of large aggregates following washout of MG132 without affecting either the
178 distribution of aggregates in the sub-critical range or R_c (**supplementary text 6** and **Fig. S6**). Our data

179 indicate that RuvBL1 dependent clearance of aggregates acts specifically on aggregates that have
180 reached a size above R_c , without changing the nucleation process.

181 The measured critical sizes, R_c , range from ~160 nm in untreated or siRNA knockdown cells,
182 to ~120 nm 3 hours after proteasome inhibition. These small magnitudes for R_c indicate that a super-
183 resolution technique is needed to unveil and measure this transition point *in vivo*, as by the time
184 individual aggregates are sufficiently large to be detected in conventional cell imaging techniques
185 they are already in the post-nucleation regime.

186 Previous studies bypass the direct observation of a nuclear barrier, and observe instead a
187 sigmoidal response in the number of visible aggregates (29). This sigmoidal response is characterized
188 by a lag-time followed by rapid growth after nucleation when a sufficiently large number of
189 aggregates have crossed the nucleation barrier. However in the living cell, biological mechanisms
190 may intervene in the post-nucleation regime to regulate the presence of larger aggregates.


191 Our results indicate that a hidden pathway may exist to clear cells of aggregates above the
192 critical size, and we have identified RuvBL1 as a necessary effector in this putative super-critical
193 clearance pathway. The mechanism by which RuvBL1, and perhaps other effectors work to
194 preferentially clear super-critical aggregates in the cell remains currently unknown. Nonetheless, the
195 agreement between our cellular super-resolution data and condensation systems with first order phase
196 transition opens an avenue in the study of protein aggregation, whereby detailed theoretical
197 predictions may be proposed and falsified experimentally, directly with quantitative *in vivo* imaging.

198 While our investigation has focused on aggregates related to Parkinsons disease, we note that
199 the methodology can be readily extended to any protein that can be fluorescently tagged (for example
200 fused to the GFP-like Dendra2). For instance, our technique may be applicable in the search for
201 intracellular manifestations of the valency driven phase separations being studied in various contexts
202 (34). Alternatively our methods could yield a thermodynamic framework underlying phase separation
203 suggested in the formation and maintenance of membraneless organelles (35). Finally There is
204 increasing evidence that the thermodynamics of first order transitions elucidated here may constitute a

205 general organizing principle for cell biology applicable for example in cellular aging (36), common
206 stress responses (37), and even in transcription (38) and other functioning of healthy cells (39). Thus
207 we anticipate that this approach can help address protein aggregation directly in cells with high
208 quantitative details, for a broad range of cellular processes and disease pathologies.

209

210




211

212 **Figure 1: Live cell super-resolution imaging unveils sub-diffractive aggregates in addition to**
213 **classically observed perinuclear inclusion.**

214 **A-E:** A single living cell expressing Dendra2-Synphillin as observed by conventional imaging (top
215 panels, green) and time-lapse super-resolution reconstructions (bottom panels, red-hot color code) is
216 represented for select time points between 105 minutes to 165 minutes after treatment with
217 proteasome inhibitor MG132. White line delineates cell nucleus; a red-hot color code is used to
218 represent the local density of detections. Both conventional and super-resolution images show the
219 gradual formation of a large perinuclear inclusion (the aggresome, see insets in bottom panel).. **F:** The
220 time-dependent sizes of individual aggresomes (gray dots) are measured from super-resolution images
221 of ten cells, illustrating cell to cell variability in the growth dynamics; the average time dependent size
222 from the ten cells is also plotted (black diamonds). In addition to the aggresomes, super-resolution
223 images (**A-E** bottom panels) reveal many sub-diffractive aggregates profusively distributed
224 throughout the cytoplasm, that were not observed by conventional imaging (**A-E** top panels). **G:** The
225 sub-diffractive aggregate size as measured by number of super-resolution localization events per
226 aggregate is plotted against the spatial size (radius cube) of aggregate. The data suggests that size of
227 sub-diffractive aggregates scales with the volume of the aggregates, suggesting a uniform density of
228 Dendra2-Synphillin detections throughout the aggregates, up to the z-axial (400 nm) cut-off of our
229 super-resolution microscope (see **supplementary text 1** for details). Data in G includes N= 4000
230 aggregates from 6 cells imaged 120 minutes after MG132 treatment.

231




232

233 **Figure 2: The time evolution of aggregate size distribution is indicative of a super-saturated**
 234 **system:** **A-C** Free energy cost of aggregate formation is plotted as a function of aggregate size as
 235 predicted by condensation theory in three different regimes. **A:** In a *sub-saturated* system free energy
 236 cost increases monotonically with aggregate size, and spontaneous disaggregation is
 237 favored (**supplementary text 2**). **B & C:** In a *super-saturated* system, a nucleation barrier exists
 238 above which free energy cost decreases with aggregate size, and spontaneous growth is favoured. **D-
 239 F:** Simulations of the aggregate size distributions as predicted by the energetics illustrated in **A, B** and
 240 **C** respectively. **D** For the *sub-saturated* system (in **A**), an exponential distribution is obtained,
 241 independent of time. **E:** For a *super-saturated* system without addition of new constituents (closed
 242 system in **B**) a time dependent distribution is obtained where by small aggregates are depleted and the
 243 system evolves towards a peak at large aggregate size. **F:** For a *super-saturated* system with addition
 244 of constituents, there is no depletion of small aggregate size, but progressive shoulder towards larger
 245 aggregate sizes is obtained with time. Insets in **D-F** represents the survival (cumulative distribution)
 246 function for the corresponding simulation. **G** Super-resolution data representing the histogram of
 247 aggregate sizes from cells fixed and imaged at three representative time points after inhibition by
 248 MG132, shows a time evolution consistent with the *super-saturated* system in **C & F**. These results
 249 indicate that aggregation in the mammalian cells are consistent with *super-saturated* condensing
 250 system. Data in **G** represents the normalized histogram from 10000 aggregates (light grey) from 10
 251 untreated cells, 6500 aggregates (grey) from 8 cells and 4000 (dark grey) from 10 cells. Details of
 252 simulation in **D-F** in (25)


253

254



255

256 **Figure 3: Aggregate size distributions are precisely described by the kinetics**
 257 **of first order phase transition. A:** The energetics of a *super-saturated* system as expected
 258 from theory on the kinetics of first order phase transition [**supplementary text 2**]. Since the
 259 expected distribution of subcritical clusters is the boltzmann (exponential) distribution, i.e.
 260 $P(n) \propto e^{-U(n)}$; With $U(n) = an^{2/3} - bn$, the energy cost dependence on cluster size can be
 261 derived from the logarithm of the distribution, i.e. $-\text{Log}(P(n))$. In the energetics, $an^{2/3}$ is a
 262 measure of surface tension of the condensing aggregates while $-bn$ is a measure of the bulk
 263 energy gain from n molecules joining an aggregate. **B** Plotting the logarithm of the
 264 distribution (histogram) of measured sub-critical aggregates (gray dots) shows the predicted
 265 curved dependence with the aggregate size (n), and fits well to the predicted energy form
 266 $U(n) = an^{2/3} - bn$. **C:** Theoretically, the surface dominates for the smallest cluster size
 267 (i.e. very low n), and subtracting the surface term from the data should result in a predicted
 268 linear dependence on cluster size (representing the resultant bulk term) i.e. $-\text{Log}(P(n)) -$
 269 $an^{2/3} \propto -bn$, or as represented here $\text{Log}(P(n)) + an^{2/3} \propto bn$. **D:** Subtracting the surface
 270 term fit for low n (here $n < 200$) yields a resultant data set that is remarkably linear, further
 271 indicating that the specific energetics of first order phase transition precisely accounts for the
 272 population of aggregates in mammalian cells. **E-F:** Further test of agreement between theory
 273 and super-resolution data is performed by treating cell with azetidine-2-carboxylic acid
 274 (AZC), and data from AZC treated cells in grey dots are compared directly with untreated
 275 cells (from **B&D**) represent with open circles. **E:** Upon AZC treatment, again, the data (grey)
 276 fit well to the predicted theoretical form (black line) **F:** With subtraction of surface term-fit
 277 for low n (here $n < 200$), the resultant also remains linear in AZC treated cells suggesting that
 278 even upon perturbation the distribution changes in a manner still consistent with the physical
 279 formalism. In addition, compared to data from untreated cells (open circles), AZC data has an
 280 increased bulk (linear) term consistent with the notion that the treatment increase the degree
 281 of *super-saturation* without changing the transition mechanism. Untreated cell data (in **B** &
 282 **D**) are from the normalized histogram of 10,000 aggregates from 10 cells and AZC data (in **E**
 283 & **F**) from 4000 aggregates from 7 cells.



284

285 **Figure 4: RuvBL1 dependent mechanism may clear super-critical aggregate in untreated cells**
286 **without affecting the nucleation barrier.** **A** Representative super-resolution reconstruction for an
287 untreated cell visually shows many sub-diffractive aggregates (dark red) but few large aggregates (red
288 hot). Red-hot color code is used to indicate the relative density of detections, and a white line
289 delineates nucleus. **B** Super-resolution reconstruction from a representative cell after RuvBL1

290 knockdown show the cytoplasmic accumulation of relatively more intense aggregates (red hot); white
291 arrows are used to indicate example super-critical aggregates; a red hot color code is used to indicate
292 the relative density of detections and a white line delineates nucleus. Insets in **A**, **B** show zoomed in
293 view of the largest, more intense aggregates found in each condition. **C** Violin plots showing the
294 distribution of observed aggregate sizes (as measured by the radius) in the untreated (black),
295 proteasome inhibited (grey) and RuvBL1 knocked-down (red) cells. Untreated cells (black) show a
296 depletion of large clusters, and RuvBL knockdown (red) rescues the population of large clusters. **D**
297 The critical radius (R_c) is plotted for untreated cells (black bar), as a function of time after MG132
298 treatment (white bars), or upon RuvBL knockdown (red bar). RuvBL knockdown (red) did not
299 significantly change R_c as compared to untreated (black) suggesting that RuvBL acted on super-
300 critical clusters (red in **C**) without significantly changing sub-critical cluster distribution (nor the
301 nucleation barrier). This is in contra MG132 treatments which gradually increased the population of
302 large aggregates (gray plots in **C**) while gradually decreasing R_c . Error bars in **D** represent errors in fit
303 estimation as described in (25). Untreated cell data are from the normalized histogram of 10,000
304 aggregates from 10 cells, RuvBL1 knockdown from 8000 aggregates from 9 cells, and inhibition data
305 from 5000-8000 aggregates from 6-10 cells per time point.

306

307

308 **References:**

- 309 1. D. J. Selkoe, Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's
310 diseases. *Nat Cell Biol* **6**, 1054-1061 (2004).
- 311 2. C. A. Ross, M. A. Poirier, Protein aggregation and neurodegenerative disease. *Nat Med* **10**
312 **Suppl**, S10-17 (2004).
- 313 3. M. R. Cookson, The biochemistry of Parkinson's disease. *Annu Rev Biochem* **74**, 29-52 (2005).
- 314 4. J. Xu *et al.*, Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for
315 selective neurodegeneration in Parkinson disease. *Nat Med* **8**, 600-606 (2002).
- 316 5. N. Gosavi, H. J. Lee, J. S. Lee, S. Patel, S. J. Lee, Golgi fragmentation occurs in the cells with
317 prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. *J Biol*
318 *Chem* **277**, 48984-48992 (2002).
- 319 6. D. L. Pountney *et al.*, Annular alpha-synuclein species from purified multiple system atrophy
320 inclusions. *J Neurochem* **90**, 502-512 (2004).
- 321 7. D. P. Karpinar *et al.*, Pre-fibrillar alpha-synuclein variants with impaired beta-structure
322 increase neurotoxicity in Parkinson's disease models. *EMBO J* **28**, 3256-3268 (2009).
- 323 8. H. A. Lashuel *et al.*, Alpha-synuclein, especially the Parkinson's disease-associated mutants,
324 forms pore-like annular and tubular protofibrils. *J Mol Biol* **322**, 1089-1102 (2002).
- 325 9. H. A. Lashuel, D. Hartley, B. M. Petre, T. Walz, P. T. Lansbury, Neurodegenerative disease:
326 amyloid pores from pathogenic mutations. *Nature* **418**, 291 (2002).
- 327 10. M. Tanaka *et al.*, Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.
328 *J Biol Chem* **279**, 4625-4631 (2004).
- 329 11. N. Zaarur, A. B. Meriin, V. L. Gabai, M. Y. Sherman, Triggering aggresome formation.
330 Dissecting aggresome-targeting and aggregation signals in synphilin 1. *J Biol Chem* **283**,
331 27575-27584 (2008).
- 332 12. J. A. Johnston, C. L. Ward, R. R. Kopito, Aggresomes: a cellular response to misfolded
333 proteins. *J Cell Biol* **143**, 1883-1898 (1998).
- 334 13. D. Kaganovich, R. Kopito, J. Frydman, Misfolded proteins partition between two distinct
335 quality control compartments. *Nature* **454**, 1088-1095 (2008).
- 336 14. A. F. Kisselev, A. L. Goldberg, Proteasome inhibitors: from research tools to drug candidates.
337 *Chem Biol* **8**, 739-758 (2001).
- 338 15. K. S. McNaught, P. Shashidharan, D. P. Perl, P. Jenner, C. W. Olanow, Aggresome-related
339 biogenesis of Lewy bodies. *Eur J Neurosci* **16**, 2136-2148 (2002).
- 340 16. C. W. Olanow, D. P. Perl, G. N. DeMartino, K. S. McNaught, Lewy-body formation is an
341 aggresome-related process: a hypothesis. *Lancet Neurol* **3**, 496-503 (2004).
- 342 17. K. Wakabayashi *et al.*, Synphilin-1 is present in Lewy bodies in Parkinson's disease. *Ann*
343 *Neurol* **47**, 521-523 (2000).
- 344 18. K. K. Chung *et al.*, Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1:
345 implications for Lewy-body formation in Parkinson disease. *Nat Med* **7**, 1144-1150 (2001).
- 346 19. D. M. Chudakov, S. Lukyanov, K. A. Lukyanov, Tracking intracellular protein movements using
347 photoswitchable fluorescent proteins PS-CFP2 and Dendra2. *Nat Protoc* **2**, 2024-2032 (2007).
- 348 20. E. Betzig *et al.*, Imaging intracellular fluorescent proteins at nanometer resolution. *Science*
349 **313**, 1642-1645 (2006).
- 350 21. M. J. Rust, M. Bates, X. Zhuang, Sub-diffraction-limit imaging by stochastic optical
351 reconstruction microscopy (STORM). *Nat Methods* **3**, 793-795 (2006).
- 352 22. S. T. Hess, T. P. Girirajan, M. D. Mason, Ultra-high resolution imaging by fluorescence
353 photoactivation localization microscopy. *Biophys J* **91**, 4258-4272 (2006).
- 354 23. W. K. Cho *et al.*, RNA Polymerase II cluster dynamics predict mRNA output in living cells. *Elife*
355 **5**, (2016).
- 356 24. I. I. Cisse *et al.*, Real-time dynamics of RNA polymerase II clustering in live human cells.
357 *Science* **341**, 664-667 (2013).
- 358 25. Materials and methods are available as supplementary materials.

- 359 26. F. Opazo, A. Krenz, S. Heermann, J. B. Schulz, B. H. Falkenburger, Accumulation and
360 clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. *J Neurochem*
361 **106**, 529-540 (2008).
- 362 27. M. Ester *et al.* (AAAI Press, Proceedings of the Second International Conference on
363 Knowledge Discovery and Data Mining (KDD-96), 1996), pp. 226-231.
- 364 28. S. H. Lee, J. Y. Shin, A. Lee, C. Bustamante, Counting single photoactivatable fluorescent
365 molecules by photoactivated localization microscopy (PALM). *Proc Natl Acad Sci U S A* **109**,
366 17436-17441 (2012).
- 367 29. A. M. Morris, M. A. Watzky, R. G. Finke, Protein aggregation kinetics, mechanism, and curve-
368 fitting: a review of the literature. *Biochim Biophys Acta* **1794**, 375-397 (2009).
- 369 30. V. V. Slezov, *Kinetics of first order phase transitions*. (Wiley-VCH, Weinheim, 2009), pp. xiv,
370 415 p.
- 371 31. F. F. Abraham, *Homogeneous nucleation theory; the pretransition theory of vapor*
372 *condensation*. Advances in theoretical chemistry Supplement (Academic Press, New York,,
373 1974), pp. xiv, 263 p.
- 374 32. A. L. Goldberg, A. C. St John, Intracellular protein degradation in mammalian and bacterial
375 cells: Part 2. *Annu Rev Biochem* **45**, 747-803 (1976).
- 376 33. N. Zaarur *et al.*, RuvbL1 and RuvbL2 enhance aggresome formation and disaggregate
377 amyloid fibrils. *EMBO J* **34**, 2363-2382 (2015).
- 378 34. P. Li *et al.*, Phase transitions in the assembly of multivalent signalling proteins. *Nature* **483**,
379 336-340 (2012).
- 380 35. C. P. Brangwynne, P. Tompa, R. V. Pappu, Polymer physics of intracellular phase transitions.
381 *Nat Phys* **11**, 899-904 (2015).
- 382 36. S. Alberti, A. A. Hyman, Are aberrant phase transitions a driver of cellular aging? *Bioessays*
383 **38**, 959-968 (2016).
- 384 37. J. A. Riback *et al.*, Stress-Triggered Phase Separation Is an Adaptive, Evolutionarily Tuned
385 Response. *Cell* **168**, 1028-1040.e1019 (2017).
- 386 38. D. Hnisz, K. Shrinivas, R. A. Young, A. K. Chakraborty, P. A. Sharp, A Phase Separation Model
387 for Transcriptional Control. *Cell* **169**, 13-23 (2017).
- 388 39. T. Amen, D. Kaganovich, Dynamic droplets: the role of cytoplasmic inclusions in stress,
389 function, and disease. *Cell Mol Life Sci* **72**, 401-415 (2015).
- 390 40. R. G. Tremblay *et al.*, Differentiation of mouse Neuro 2A cells into dopamine neurons. *J*
391 *Neurosci Methods* **186**, 60-67 (2010).
- 392 41. A. Sergé, N. Bertaux, H. Rigneault, D. Marguet, Dynamic multiple-target tracing to probe
393 spatiotemporal cartography of cell membranes. *Nat Methods* **5**, 687-694 (2008).
- 394 42. M. Ester *et al.* (AAAI Press, Proceedings of the Second International Conference on
395 Knowledge Discovery and Data Mining (KDD-96), 1996), pp. 226-231.
- 396 43. J. O. Andrews *et al.*, qSR: A software for quantitative analysis of single molecule and super-
397 resolution data. *bioRxiv*, (2017).
- 398 44. F. Balzarotti *et al.*, Nanometer resolution imaging and tracking of fluorescent molecules with
399 minimal photon fluxes. *Science* **355**, 606-612 (2017).
- 400 45. J. Schmelzer, G. Ropke, F.-P. Ludwig, Nuclear multifragmentation processes and nucleation
401 theory. **55**, 1917 (1997).
- 402 46. S. A. Tanik, C. E. Schultheiss, L. A. Volpicelli-Daley, K. R. Brunden, V. M. Lee, Lewy body-like α -
403 synuclein aggregates resist degradation and impair macroautophagy. *J Biol Chem* **288**,
404 15194-15210 (2013).
- 405 47. M. Kato *et al.*, Cell-free formation of RNA granules: low complexity sequence domains form
406 dynamic fibers within hydrogels. *Cell* **149**, 753-767 (2012).
- 407 48. R. Halfmann *et al.*, Prions are a common mechanism for phenotypic inheritance in wild
408 yeasts. *Nature* **482**, 363-368 (2012).

410 Statement of Conflict of interests: The authors declare no conflict of interests

411 Acknowledgments: We thank Kabir Ramola (Brandeis), Jeff Gore (MIT), Kandice Tanner
412 (NCI/NIH) as well as members of the Cissé lab at MIT (Jan Hendrik Spille, and Micca Hecht) for
413 helpful comments and discussions. Research reported in this publication was supported by the
414 National Cancer Institute and the National Institutes of Health through the NIH Director's New
415 Innovator Award Number DP2CA195769 to IIC. The content is solely the responsibility of the
416 authors and does not necessarily represent the official views of the National Institutes of Health. This
417 work was also supported by funds from the MIT Department of Physics.

418 **Supplementary Materials:**

419 Materials and Methods

420 Supplementary text 1-6

421 Tables S1-S6

422 Movies S1

423 References (11, 31, 30, 40-48)

424